Associated Genetic Biomarkers

Overview

Clinical Trials

There
are 16 clinical trials
for small lymphocytic leukemia, of which 13
are
open and 3
are
completed or closed.
Of the
trials that contain
small lymphocytic leukemia as an inclusion criterion, 7 are phase 1 (5 open), 5 are phase 1/phase 2 (5 open), and 4 are phase 2 (3 open).

MECOM, RPN1, and ABL1
are the most frequent gene inclusion
criteria for
small lymphocytic leukemia clinical trials [3].

Trials Investigating Small Lymphocytic Leukemia by Gene and Recruiting Status

Ibrutinib, rituximab, and lenalidomide
are the most common
interventions in
small lymphocytic leukemia clinical trials.

Drugs Being Investigated in Small Lymphocytic Leukemia Trials by Recruiting Status

Significant Genes in Small Lymphocytic Leukemia

ABL1
+

ABL1 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
ABL1 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

AFF1
+

AFF1 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
AFF1 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

BCR
+

BCR is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
BCR status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

CBFB
+

CBFB is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
CBFB status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

DEK
+

DEK is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
DEK status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

ELL
+

ELL is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
ELL status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

FLT3
+

FLT3 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
FLT3 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

KIT
+

KIT is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
KIT status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2A
+

KMT2A is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
KMT2A status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MECOM
+

MECOM is an inclusion eligibility criterion in 2 clinical
trials
for small lymphocytic leukemia, of which 1
is open and 1
is closed.
Of the
trials that contain
MECOM status and small lymphocytic leukemia as inclusion criteria, 2 are phase 1 (1 open) [3].

MLF1
+

MLF1 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 1
is open and 0
are closed.
Of the
trial that contains
MLF1 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

MLLT1
+

MLLT1 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
MLLT1 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT10
+

MLLT10 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
MLLT10 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT3
+

MLLT3 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
MLLT3 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MLLT4
+

MLLT4 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
MLLT4 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

MYC
+

MYC is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 1
is open and 0
are closed.
Of the
trial that contains
MYC status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYH11
+

MYH11 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
MYH11 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

NPM1
+

NPM1 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 1
is open and 0
are closed.
Of the
trial that contains
NPM1 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [3].

NUP214
+

NUP214 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
NUP214 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

RPN1
+

RPN1 is an inclusion eligibility criterion in 2 clinical
trials
for small lymphocytic leukemia, of which 1
is open and 1
is closed.
Of the
trials that contain
RPN1 status and small lymphocytic leukemia as inclusion criteria, 2 are phase 1 (1 open) [3].

RUNX1
+

RUNX1 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
RUNX1 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

RUNX1T1
+

RUNX1T1 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
RUNX1T1 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

TP53
+

TP53 is an inclusion eligibility criterion in 1 clinical
trial
for small lymphocytic leukemia, of which 0
are open and 1
is closed.
Of the
trial that contains
TP53 status and small lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

Disease Details

Parent(s)

Mature B-Cell Neoplasm

References

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.